Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSNASDAQ:ETTXNASDAQ:FWPNASDAQ:HOTHOTCMKTS:RGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03+22.9%$0.06$0.00▼$0.78$1.42M1.185,966 shs1,720 shsETTXEntasis Therapeutics$2.19$2.19$1.40▼$3.88$104.80M1.33239,104 shs800 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AHOTHHoth Therapeutics$1.17+3.5%$1.03$0.58▼$3.80$14.93M0.553.71 million shs412,756 shsRGRXRegeneRx Biopharmaceuticals$0.00$0.00$0.00▼$0.07N/A3.0317 shs13 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals+22.88%-72.32%-2.63%+11.00%-87.97%ETTXEntasis Therapeutics0.00%0.00%0.00%0.00%0.00%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%HOTHHoth Therapeutics+3.54%-4.49%+39.39%+20.04%+28.67%RGRXRegeneRx Biopharmaceuticals0.00%0.00%0.00%-85.71%-85.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AETTXEntasis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AHOTHHoth Therapeutics2.0382 of 5 stars3.62.00.00.02.40.00.6RGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AETTXEntasis Therapeutics 0.00N/AN/AN/AFWPForward Pharma A/S 0.00N/AN/AN/AHOTHHoth Therapeutics 3.25Buy$4.00241.88% UpsideRGRXRegeneRx Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FWP, ETTX, ADXS, HOTH, and RGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.44N/AN/A($2.06) per share-0.02ETTXEntasis Therapeutics$7M14.97N/AN/A$0.66 per share3.32FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/ARGRXRegeneRx Biopharmaceuticals$80K0.00N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AETTXEntasis Therapeutics-$47.14M-$1.12N/AN/AN/AN/A-145.48%-103.75%N/AFWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AHOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)RGRXRegeneRx Biopharmaceuticals-$1.73MN/A0.00∞N/AN/AN/AN/AN/ALatest FWP, ETTX, ADXS, HOTH, and RGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AETTXEntasis TherapeuticsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AETTXEntasis TherapeuticsN/A1.651.65FWPForward Pharma A/SN/A18.43N/AHOTHHoth TherapeuticsN/A15.0915.08RGRXRegeneRx BiopharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ETTXEntasis Therapeutics6.91%FWPForward Pharma A/S12.57%HOTHHoth Therapeutics7.08%RGRXRegeneRx BiopharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ETTXEntasis Therapeutics6.50%FWPForward Pharma A/S71.47%HOTHHoth Therapeutics6.92%RGRXRegeneRx Biopharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableETTXEntasis Therapeutics5147.85 million44.74 millionNot OptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableHOTHHoth Therapeutics413.21 million12.30 millionNot OptionableRGRXRegeneRx Biopharmaceuticals31.51 million1.32 millionNot OptionableFWP, ETTX, ADXS, HOTH, and RGRX HeadlinesRecent News About These CompaniesEIGRQ Eiger BioPharmaceuticals, Inc.July 19, 2024 | seekingalpha.comThe Hawryluk Biopharmaceutical ScholarsJanuary 1, 2024 | kellogg.northwestern.eduKRegenerx Biopharmaceuticals Inc RGRXDNovember 5, 2023 | morningstar.comMRegenerx Biopharm In (RGRXD)October 30, 2023 | investing.comLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater ChinaSeptember 21, 2023 | businesswire.comJeannette company becomes leader in recycling biopharmaceutical wasteSeptember 18, 2023 | triblive.comTRGRX RegeneRx Biopharmaceuticals, Inc.August 26, 2023 | seekingalpha.comRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting ObligationsAugust 15, 2023 | finance.yahoo.comRegeneRx Receives Stockholder Approval for Reverse Stock SplitAugust 8, 2023 | finance.yahoo.comRegeneRx To Extend Consent Solicitation VoteAugust 1, 2023 | finance.yahoo.comBristol-Myers to Split Off Mead JohnsonJuly 6, 2023 | thestreet.comPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage InitiationMay 19, 2023 | thestreet.comFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259April 13, 2023 | finance.yahoo.comBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030April 7, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029April 7, 2023 | marketwatch.comCURIA, CORNING BOOST BIOPHARMACEUTICAL CONTINUOUS-FLOW DEVELOPMENT, MANUFACTURINGApril 4, 2023 | bernama.comB2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029March 1, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 24, 2023 | marketwatch.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)February 12, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFWP, ETTX, ADXS, HOTH, and RGRX Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.03 +0.01 (+22.88%) As of 06/30/2025 11:15 AM EasternAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Entasis Therapeutics NASDAQ:ETTXEntasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.Forward Pharma A/S NASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Hoth Therapeutics NASDAQ:HOTH$1.17 +0.04 (+3.54%) As of 06/30/2025 04:00 PM EasternHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.RegeneRx Biopharmaceuticals OTCMKTS:RGRX$0.0002 0.00 (0.00%) As of 06/27/2025RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.